This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Layoffs Continue to Mount

Amgen

Biotechnology giant Amgen (AMGN - Get Report) said on Oct. 19 that it is laying off 380 employees in its research and development division. This represents about 6% of its total workforce.

The company said it is restructuring these operations in the effort to better allocate its research and development resources.

In its second quarter, Amgen spent 26% more in research to $808 million. In a statement, Amgen said it has experimental drugs moving into expensive, late-stage patient testing so it must shift some research and development resources to invest in the testing and other work related to getting the experimental medicines approved.

2 of 52

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG
AMGN $158.95 -0.31%
CMC $16.11 -0.74%
LOW $70.77 0.48%
NYT $13.43 -1.25%
AAPL $125.01 -0.63%

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs